Integrated Drug Development at 9:00 am – 10:00 am  Rick Panicucci is the Senior Vice President CMC at QED Therapeutics and Origin Biosciences. Prior to joining BridgeBio, Rick served as VP of Pharmaceutical Development Services at WuXi STA, where he provided scientific leadership in formulation development and GMP manufacturing. From 2004 to 2015, Rick Panicucci was Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis. His responsibilities included analytics, solid-state chemistry, and formulation development for all small molecule therapeutics. He also helped develop novel drug delivery technologies for small molecules and large molecules including oligonucleotides. Rick has also led R&D groups at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. Rick Panicucci received his PhD in Physical Organic Chemistry at the University of Toronto and has two post-doctoral fellowships at the University of California at Santa Barbara and the Ontario Cancer Institute